FindTrial
Sign In

A comparison of the effect of a blood component and steroid injection in the wrist of patients with carpal tunnel syndrome

A Randomised Control Trial to Compare the effect of Single dose Platelet Rich Plasma and Corticosteroid Injection in patients with Carpal tunnel syndrome

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009696
Enrollment
84
Registered
2017-09-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Carpal Tunnel syndrome Health Condition 2: G560- Carpal tunnel syndrome

Interventions

Intervention1: Platelet rich plasma: 1 ml Single dose USG guided, one time, perineurial injection into the median nerve of the affected wrist Control Intervention1: Corticosteroid: 1 ml Single dose

Sponsors

Department of PMR
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed cases of Carpal Tunnel Syndrome 2. Failure of conservative management for 4 weeks

Exclusion criteria

Exclusion criteria: 1.Local skin infection at the site of injection 2.Diagnosed cases of platelet dysfunction and Thrombocytopenia (Platelet 3.Diagnosed cases of Malignancy 4.Uncontrolled endocrine dysfunction (Type 2 Diabetes mellitus (FBS >110mg/dl, PPBS >140mg/dl), Hypothyroidism ( >3.3mIU/L) ) Hb 5.Severe CTS with thenar muscle atrophy (Mackinnsonââ?¬•s classification) 6.Diagnosed cases of rheumatoid arthritis 7.Prior surgery or fracture in the same wrist 8.Prior steroid injection in the same wrist within 6 months of the study 9.Patient on anticoagulant therapy 10.Refusal to participate in the study

Design outcomes

Primary

MeasureTime frame
Improvement in functional outcome (BCTQ-functional outcome score)Timepoint: 4th week and 12th week—

Secondary

MeasureTime frame
Changes in CSA of median nerve at carpal tunnel (USG)Timepoint: 4th week and 12th week;Improvement in symptom severity (BCTQ- symptom severity score)Timepoint: 4th week and 12th week—

Countries

India

Contacts

Public ContactDr Srikumar V

AIIMS ; New Delhi

srikumar.venkataraman@gmail.com9868308196

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026